Oncology
Clinical Study
Lobular Breast Cancer and Abdominal Metastases: A Retrospective Review and Impact on SurvivalWinn J.S.b · Baker M.G.c · Fanous I.S.a · Slack-Davis J.K.a · Atkins K.A.a · Dillon P.M.aaUniversity of Virginia Health System, Charlottesville, Va., bFox Chase Cancer Center, Philadelphia, Pa., and cYale School of Medicine, New Haven, Conn., USA
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: May 24, 2016
Accepted: May 24, 2016
Published online: June 30, 2016
Issue release date: September 2016
Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Abstract
Background: The predominant breast cancer subtypes, invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC), have similar recurrence and survival rates but differing patterns of metastatic recurrence. Methods: A retrospective review of breast cancers treated at an academic medical center from 1999 to 2012 was performed. Demographic, pathologic, treatment, and follow-up data were collected for 179 ILC and 358 IDC patients (1:2 stage-matched). The median follow-up was 4.7 years. Results: The baseline characteristics were similar in the two groups. ILC was more likely to be hormone-receptor-positive/HER2-negative and mammographically occult. The number of surgical resections, breast conservation rate, systemic treatment, and taxane use was similar between the groups. The overall recurrence rate was the same. ILC recurred more often in the abdominal cavity (24.3% in ILC vs. 4.1% in IDC, p = 0.001). The disease-free survival and overall survival were equal. On multivariate analysis, age, stage of disease, hormone receptor status, and systemic therapy were associated with survival, but histology was not. Conclusions: Compared to ductal breast cancers, lobular breast cancers recur more often in the abdominal cavity. Both ILC and IDC have comparable surgical and medical treatment outcomes and survival. Our data suggest that enhanced surveillance and imaging might be useful in ILC.
© 2016 S. Karger AG, Basel
Related Articles:
References
- Li CI, Uribe DJ, Daling JR: Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005;93:1046-1052.
- Harris JR, Lippman ME, Veronesi U, et al: Breast cancer. N Engl J Med 1992;327:390-398.
- Sastre-Garau X, Jouve M, Asselain B, et al: Infiltrating lobular carcinoma of the breast: clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer 1996;77:113-120.
- Arpino G, Bardou VJ, Clark GM, et al: Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 2004;6:R149-R156.
- Kwast AB, Groothuis-Oudshoorn KC, Grandjean I, et al: Histological type is not an independent prognostic factor for the risk pattern of breast cancer recurrences. Breast Cancer Res Treat 2012;135:271-280.
- Wasif N, Maggard MA, Ko CY, et al: Invasive lobular vs. ductal breast cancer: a stage-matched comparison of outcomes. Ann Surg Oncol 2010;17:1862-1869.
- Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al: Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2004;23:41-48.
- Santiago RJ, Harris EER, Qin L, et al: Similar long-term results of breast-conservation treatment for stage I and II invasive lobular carcinoma compared with invasive ductal carcinoma of the breast. Cancer 2005;103:2447-2454.
- Vo TN, Meric-Bernstam F, Yi M, et al: Outcomes of breast-conservation therapy for invasive lobular carcinoma are equivalent to those for invasive ductal carcinoma. Am J Surg 2006;192:552-555.
- Ferlicot S, Vincent-Salomon A, Médioni J, et al: Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 2004;40:336-341.
- Pestalozzi BC: Portrait of invasive lobular carcinoma of the breast. Eur J Cancer 2009;45:450-451.
- Pestalozzi BC, Zahrieh D, Mallon E, et al: Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 international breast cancer study group clinical trials. J Clin Oncol 2008;26:3006-3014.
- Jain S, Fisher C, Smith P, et al: Patterns of metastatic breast cancer in relation to histological type. Eur J Cancer 1993;29:2155-2157.
- Oliveira NC, Gomig TH, Milioli HH, et al: Comparative proteomic analysis of ductal and lobular invasive breast carcinoma. Genet Mol Research 2016;15.
- Rakha EA, El-Sayed ME, Powe DG, et al: Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes. Eur J Cancer 2008;44:73-83.
- Lagendijk JH, Mullink H, van Diest PJ, et al: Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol 1999;52:283-290.
- Ali S, Kaur J, Patel KD: Intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and regulated on activation normal T cell expressed and secreted are expressed by human breast carcinoma cells and support eosinophil adhesion and activation. Am J Pathol 2000;157:313-321.
- Morrogh M, Andrade VP, Giri D, et al: Cadherin-catenin complex dissociation in lobular neoplasia of the breast. Breast Cancer Res Treat 2011;132:641-652.
- Borst MJ, Ingold JA: Metastatic patterns of invasive lobular versus invasive ductal carcinoma of the breast. Surgery 1993;114:637-641; discussion 641-642.
- Toikkanen S, Pylkkänen L, Joensuu H: Invasive lobular carcinoma of the breast has better short- and long-term survival than invasive ductal carcinoma. Br J Cancer 1997;76:1234-1240.
- Fortunato L, Mascaro A, Poccia I, et al: Lobular breast cancer: same survival and local control compared with ductal cancer, but should both be treated the same way? Analysis of an institutional database over a 10-year period. Ann Surg Oncol 2011;19:1107-1114.
- Molland JG, Donnellan M, Janu NC, et al: Infiltrating lobular carcinoma - a comparison of diagnosis, management and outcome with infiltrating duct carcinoma. Breast 2004;13:389-396.
- Orvieto E, Maiorano E, Bottiglieri L, et al: Clinicopathologic characteristics of invasive lobular carcinoma of the breast. Cancer 2008;113:1511-1520.
- Krecke KN, Gisvold JJ: Invasive lobular carcinoma of the breast: mammographic findings and extent of disease at diagnosis in 184 patients. Am J Roentgenol 1993;161:957-960.
- Moran MS, Yang Q, Haffty BG: The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology. Breast J 2009;15:571-578.
- Parvaiz MA, Yang P, Razia E, et al: Breast MRI in invasive lobular carcinoma: a useful investigation in surgical planning? Breast J 2016;22:143-150.
- Sinclair K, Sakellariou S, Dawson N, et al: Does preoperative breast MRI significantly impact on initial surgical procedure and re-operation rates in patients with screen-detected invasive lobular carcinoma? Clin Radiol 2016;71:543-550.
- Doria MT, Maesaka JY, Martins SN, et al: Gastric metastasis as the first manifestation of an invasive lobular carcinoma of the breast. Autops Case Rep 2015;5:49-53.
- McLemore EC, Pockaj BA, Reynolds C, et al: Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. Ann Surg Oncol 2005;12:886-894.
- Kowalski PJ, Rubin MA, Kleer CG: E-cadherin expression in primary carcinomas of the breast and its distant metastases. Breast Cancer Res 2003;5:R217.
- Gruel N, Lucchesi C, Raynal V, et al: Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma. Eur J Cancer 2010;46:2399-2407.
Article / Publication Details
Received: May 24, 2016
Accepted: May 24, 2016
Published online: June 30, 2016
Issue release date: September 2016
Number of Print Pages: 8
Number of Figures: 2
Number of Tables: 3
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
